These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29794406)

  • 1. Inter-individual Comparison of Gadobutrol and Gadoteridol Tissue Time-intensity Profiles for Dynamic Susceptibility Contrast Perfusion MR Imaging.
    Yamada M; Taoka T; Kawaguchi A; Yasuda K; Niinomi Y; Ohashi Y; Okuda T; Naganawa S
    Magn Reson Med Sci; 2019 Jan; 18(1):75-81. PubMed ID: 29794406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic susceptibility MR perfusion imaging of the brain: not a question of contrast agent molarity.
    Panara V; Chiacchiaretta P; Rapino M; Maruotti V; Parenti M; Piccirilli E; Pizzi AD; Caulo M
    Neuroradiology; 2022 Apr; 64(4):685-692. PubMed ID: 34557937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal Enhancement and Enhancement Kinetics of Gadobutrol, Gadoteridol, and Gadoterate Meglumine in Various Body Regions: A Comparative Animal Study.
    Knobloch G; Frenzel T; Pietsch H; Jost G
    Invest Radiol; 2020 Jun; 55(6):367-373. PubMed ID: 31985602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arterial first pass gadolinium-CM dynamics as a function of several intravenous saline flush and Gd volumes.
    Boos M; Scheffler K; Haselhorst R; Reese E; Fröhlich J; Bongartz GM
    J Magn Reson Imaging; 2001 Apr; 13(4):568-76. PubMed ID: 11276101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).
    Maravilla KR; Smith MP; Vymazal J; Goyal M; Herman M; Baima JJ; Babbel R; Vaneckova M; Žižka J; Colosimo C; Urbańczyk-Zawadzka M; Mechl M; Bag AK; Bastianello S; Bueltmann E; Hirai T; Frattini T; Kirchin MA; Pirovano G
    AJNR Am J Neuroradiol; 2015 Jan; 36(1):14-23. PubMed ID: 25300984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Gadolinium Concentrations within Multiple Rat Organs after Intravenous Administration of Linear versus Macrocyclic Gadolinium Chelates.
    McDonald RJ; McDonald JS; Dai D; Schroeder D; Jentoft ME; Murray DL; Kadirvel R; Eckel LJ; Kallmes DF
    Radiology; 2017 Nov; 285(2):536-545. PubMed ID: 28640692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
    Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
    Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T.
    Essig M; Lodemann KP; Le-Huu M; Brüning R; Kirchin M; Reith W
    Invest Radiol; 2006 Mar; 41(3):256-63. PubMed ID: 16481908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol.
    Tombach B; Benner T; Reimer P; Schuierer G; Fallenberg EM; Geens V; Wels T; Sorensen AG
    Radiology; 2003 Mar; 226(3):880-8. PubMed ID: 12601217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents.
    Tweedle MF
    Invest Radiol; 1992 Aug; 27 Suppl 1():S2-6. PubMed ID: 1506149
    [No Abstract]   [Full Text] [Related]  

  • 11. Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care.
    Varallyay CG; Nesbit E; Horvath A; Varallyay P; Fu R; Gahramanov S; Muldoon LL; Li X; Rooney WD; Neuwelt EA
    J Magn Reson Imaging; 2018 Aug; 48(2):441-448. PubMed ID: 29314418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
    Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain DSC MR Perfusion in Children: A Clinical Feasibility Study Using Different Technical Standards of Contrast Administration.
    Gaudino S; Martucci M; Botto A; Ruberto E; Leone E; Infante A; Ramaglia A; Caldarelli M; Frassanito P; Triulzi FM; Colosimo C
    AJNR Am J Neuroradiol; 2019 Feb; 40(2):359-365. PubMed ID: 30655255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First in vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable high field relaxivity.
    Livramento JB; Weidensteiner C; Prata MI; Allegrini PR; Geraldes CF; Helm L; Kneuer R; Merbach AE; Santos AC; Schmidt P; Tóth E
    Contrast Media Mol Imaging; 2006; 1(1):30-9. PubMed ID: 17193598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical properties, pharmacokinetics, and biodistribution of gadoteridol injection in rats and dogs.
    Eakins MN; Eaton SM; Fisco RA; Hunt RJ; Ita CE; Katona T; Owies LM; Schramm E; Sulner JW; Thompson CW
    Acad Radiol; 1995 Jul; 2(7):584-91. PubMed ID: 9419608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Relaxivities of Macrocyclic Gadolinium-Based Contrast Agents in Human Plasma at 1.5, 3, and 7 T, and Blood at 3 T.
    Szomolanyi P; Rohrer M; Frenzel T; Noebauer-Huhmann IM; Jost G; Endrikat J; Trattnig S; Pietsch H
    Invest Radiol; 2019 Sep; 54(9):559-564. PubMed ID: 31124800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of cerebral perfusion by first-pass, dynamic, contrast-enhanced, steady-state free-precession MR imaging: an animal study.
    Runge VM; Kirsch JE; Wells JW; Woolfolk CE
    AJR Am J Roentgenol; 1993 Mar; 160(3):593-600. PubMed ID: 8430562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadolinium Deposition in the Brain in a Large Animal Model: Comparison of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Radbruch A; Richter H; Fingerhut S; Martin LF; Xia A; Henze N; Paulus W; Sperling M; Karst U; Jeibmann A
    Invest Radiol; 2019 Sep; 54(9):531-536. PubMed ID: 31261291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course for measuring endolymphatic size in healthy volunteers following intravenous administration of gadoteridol.
    Naganawa S; Suzuki K; Yamazaki M; Sakurai Y; Ikeda M
    Magn Reson Med Sci; 2014; 13(2):73-80. PubMed ID: 24769637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats.
    Bussi S; Coppo A; Botteron C; Fraimbault V; Fanizzi A; De Laurentiis E; Colombo Serra S; Kirchin MA; Tedoldi F; Maisano F
    J Magn Reson Imaging; 2018 Mar; 47(3):746-752. PubMed ID: 28730643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.